^
9ms
AMELI-01: Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=65, Recruiting, Cellectis S.A. | Trial completion date: Mar 2023 --> Dec 2024 | Trial primary completion date: Mar 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
IL3RA (Interleukin 3 Receptor Subunit Alpha)
|
UCART123
over1year
AMELI-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML) (ASGCT 2023)
AMELI-01 (NCT04106076) is a phase 1 trial evaluating the safety, tolerability, expansion, and persistence of UCART123 given at escalating dose levels after LD with either fludarabine and cyclophosphamide (FC) or FC with alemtuzumab (FCA) in patients (pts) with R/R AML.Key eligibility criteria include pts 18-65 yrs, adequate organ function, ECOG PS ≤ 1, and blasts positive for CD123 by flow cytometry. Pts must have received ≥2 cycles of chemotherapy, ≥ 1 cycle of a high/intermediate dose cytarabine containing regimen, ≥ 2 cycles of an HMA combination regimen, or prior allogeneic HSCT...Overall, these data support the safety and activity of UCART123 after FCA LD in pts with CD123+ R/R AML. Based on observed UCART123 expansion patterns and cytokine profiles, the study was amended to include a UCART123 2-dose regimen with FCA LD, and enrollment is ongoing into this arm​.
Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
|
CD123 (Interleukin 3 Receptor Subunit Alpha)
|
CD123 positive • CD123 expression
|
cytarabine • cyclophosphamide • Campath (alemtuzumab) • fludarabine IV • UCART123
2years
Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML) (ASH 2022)
AMELI-01 (NCT04106076) is a phase 1, open-label, dose-escalation trial evaluating the safety, tolerability, expansion, and persistence of UCART123v1.2 given at escalating dose levels after LD with either fludarabine and cyclophosphamide (FC) or FC with alemtuzumab (FCA) in patients (pts) with R/R CD123+ AML...Pts must have received ≥2 cycles of chemotherapy (one with standard dose cytarabine), ≥ 1 cycle of a high/intermediate dose cytarabine containing regimen, ≥ 2 cycles of an HMA combination regimen, or prior allogeneic HSCT... Adding alemtuzumab to the FC regimen was associated with improved LD and significantly higher UCART123v1.2 cell expansion and persistence, which correlated with improved activity and safety, including one pt in the DL2 FCA arm who achieved a durable MRD-negative CR. Overall, these data support the safety and activity of UCART123v1.2 after FCA LD in pts with CD123+ R/R AML.
Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL15 (Interleukin 15)
|
CD123 positive • CD123 expression
|
cytarabine • cyclophosphamide • Campath (alemtuzumab) • fludarabine IV • UCART123 • CART123
over2years
Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia. (PubMed, Nat Commun)
As safety feature, cells express RQR8 to allow elimination with Rituximab. Furthermore, UCART123 preferentially target AML over normal cells with modest toxicity to normal hematopoietic stem/progenitor cells. Together these results suggest that UCART123 represents an off-the shelf therapeutic approach for AML.
Journal • CAR T-Cell Therapy
|
CD123 (Interleukin 3 Receptor Subunit Alpha)
|
Rituxan (rituximab) • UCART123
4years
[VIRTUAL] Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia (ASH 2020)
Also, the CAR is co-expressed with a suicide mechanism (RQR8), which can be activated by using rituximab...Pts receive a lymphodepletion (LD) regimen of either fludarabine and cyclophosphamide (FC) or fludarabine, cyclophosphamide plus alemtuzumab (FCA) starting on Day -5, followed by an infusion of UCART123 at one of 5 dose levels on Day 0...DL1 has cleared safety without DLT, and enrollment at the next dose levels are proceeding. ClinicalTrials.gov Identifier: NCT03190278
Clinical
|
CD123 (Interleukin 3 Receptor Subunit Alpha)
|
Rituxan (rituximab) • Campath (alemtuzumab) • fludarabine IV • UCART123 • CTL123 • cyclophosphamide intravenous